Category Archives: IBB

Biotech … Downside Reversal?

August 16, 2026 By in Biotech, IBB, IBB-26-02, Karen Kingston, Speck-Effect, The Speck, Up-Thrust, Wyckoff Leave a comment

Alignment of Forces

The last two updates, here and here, presented the case, forces are lining up; probability’s increasing for a downside reversal.

This update will complete the session (so far) on that potential.

Let’s not forget, behind-the-scenes (for years) stories like this and this continue to bubble to the surface.

Biotech IBB, Weekly

Last week’s trading range was significantly more narrow (with volume higher) than the week prior.

The chart shows IBB finished at or near the top of the wedge boundary and in Wyckoff ‘up-thrust’ position.

The ‘more’ promised at the end of yesterday’s update; Friday’s daily volume contracted on the test.

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech ‘Dissected’

August 15, 2026 By in Biotech, IBB, IBB-26-02 1 Comment

Looking at The Inside

Yesterday’s update showed biotech sector IBB, in a bearish divergence.

The list of components can be found here.

For today, we’ll look at some of the technical characteristics pointing to potential for a downside reversal (not advice, not a recommendation).

Biotech IBB, Weekly

A wedge typically occurs at the end of a move, whether up or down (not advice, not a recommendation).

Price action has met the ‘measured move’ target and even gone slightly above.

The potential bearish MACD is shown.

If the coming week is flat or down, we’ll (likely) have a tick lower in MACD, completing the divergence signal.

Fo the next update, we’ll discuss a much larger ‘terminating’ wedge and more.

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech’s Dual Divergence

August 14, 2026 By in Biotech, IBB, IBB-26-02, Spring-to-Up-Thrust 2 Comments

Daily & Weekly

The daily chart of IBB (left), and the weekly, are both posting bearish divergences.

Caveat: Strictly speaking, on the weekly chart, the MACD has yet to tick lower.

However, if next week’s action holds steady or posts lower, we’ll likely get that signal as well (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Monday’s Damage Assessment

October 13, 2025 By in $SPSIBI, Bert Dohmen, BIS, DRIP, DRV, DUST, DXD, FAZ, IBB, JDST, LABD, LABD-25-13, Positions, QID, SDS, SOXS, SPBIO, TZA, XBI

Where’s The Crash?

The YouTube weekend ‘consensus’ was for a Monday morning massacre.

So, where is it?

Bert Dohmen, said it best in this interview, (paraphrasing), ‘If everybody agrees with our analysis, then we have to get a new analysis’.

Monday’s First 15-Minutes

After the first 15-minutes of trade, an assessment was made on the ‘Leveraged Inverse Funds’.

The point being, since this site’s maintaining a short position in biotech (via LABD), how did it fare when compared to the other funds?

After the first 15-minutes of trade, the table at left shows all inverse funds being tracked, in the red, some painfully so (like SOXS, JDST, DUST).

All red, except for the two biotech’s, LABD and BIS.

Those two funds are short vehicles for biotech XBI and IBB, respectively.

The XBI index has not (yet) made a new daily low.

Conversely, the inverse fund LABD, has not made a new daily high.

With that said, the stop on LABD-25-13, remains at last Friday’s low of 33.17 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Markets Blow-Up … A Review

October 11, 2025 By in $SPSIBI, Bonds, CDNS, DIA, Dow 30, IBB, Natural Gas, SPBIO, TLT, UNG, WFC, Wyckoff, XBI

In The Aggregate

Whether or not we’re at the ‘anxiety’ point shown on the chart, is yet to be seen.

Markets are open this coming Monday, except for bonds, adding to the weekend angst.

Reviewing The (past) Week

Posts over last week, even the weeks before, showed from a Wyckoff perspective, something was about to happen.

Cadence Design … Reversal Ready, link here.

When The Bonds Spike, link here.

Wells Fargo Top … 86.66, link here.

Biotech (short) Set-Up, link here.

Top of The Dow, link here.

In retrospect and in aggregate, it’s now obvious something was amiss.

The ‘Art’ of Wyckoff

Wyckoff technique is more art than science, more intuitive than calculated, more ephemeral than certain.

We’ll get into what happens when logic overrides that art, in the next update; Nat-Gas UNG.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech (short) Set-Up

October 9, 2025 By in $SPSIBI, IBB, LABD, LABD-25-13, Positions, SPBIO, Up-Thrust, XBI 3 Comments

Breakout Into Resistance

Both biotech funds, IBB, and XBI, are now in an up-thrust (potential reversal) condition.

In each case, the ETFs have pushed through a long-established trading range, straight into resistance.

The last update focused on less liquid IBB, because it was not known if heavily traded XBI, would push through its trading range (being the weaker of the two).

Since that initial update, both indices are now above their trading range.

Of course, what happens next is the question.

Biotech XBI, Weekly

The blue line is long established resistance.

The black dashed line is the top of the trading range and the up-thrust condition.

At this point anything can happen.

XBI, could reverse immediately or grind its way along, dissipate momentum, or even move higher.

We’re at the point where the risk of being wrong on a short position is least (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech At The Edge

October 7, 2025 By in Biotech, BIS, BIS-25-01, IBB, Positions, Spring-to-Up-Thrust 1 Comment

Where The Risk Is Least

Biotech tracking fund IBB, has posted itself into an interesting position.

Last week, it launched higher over +7% and penetrated long established resistance; this week, it has essentially stopped dead.

Biotech IBB, Weekly

If what we have is the repeating pattern of ‘spring-to-up-thrust’, it’s happening on a massive scale.

For a short position, the broker being used indicates HTB (Hard To Borrow); there are potential fees associated with selling short.

With that said, the 2X leveraged Inverse fund is BIS. However, it too has problems. It’s not liquid; typically, 14K – 20K shares a day.

Nonetheless, short established via BIS (BIS-25-01) with stop at the week’s low of 11.95 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Bubble’ & The ‘Beast’

September 26, 2025 By in $SPSIBI, Artificial Intelligence, Biotech, BIS, IBB, Positions, Semiconductors, SOXS, SOXX, SOXX-25-14, SPBIO, Up-Thrust, Wyckoff, XBI 3 Comments

Downside For Both?

The ‘bubble’ is obvious, Artificial Intelligence.

The ‘beast’, not so much, but revealed below.

The last update, presented a case for the SOXX top, a proxy for A.I.

Note: If the SOXX, has made its final high, it’s still very early in the reversal:

Wyckoff said a century ago, ‘It’s as if the weight of a feather can move the market in either direction’.

That’s where we are now.

For biotech (IBB, XBI), different forces are at work.

Biotech IBB, Weekly

The 38.2%, retrace from 9/19 high, to 9/25 low, is in the vicinity of 140.90 (magenta dashed line).

Fridays are typically biased to the upside.

There’s a possibility IBB, may test (upward) throughout the session, heading to (at or near) 38%, by the end of the day (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Margin Debt … $1-Trillion

September 18, 2025 By in $SPSIBI, Biotech, DIA, IBB, IWM, IYR, LABD, LABD-25-11, Positions, QQQ, S&P, S&P 500, SPBIO, SPY, Up-Thrust, Wyckoff, XBI, XLF, ZeroHedge

When it Implodes

Is the bell ringing?

Is this it?

In the pre-market, SPY, DIA, XLF, QQQs, all-time highs.

Meanwhile, beneath the surface, it’s getting a bit ‘uncomfortable’.

One Trillion in margin debt as reported here and here.

The Ones To Watch

While all eyes are focused on the leaders (above), at least three markets are not participating:

Real Estate, IYR, Russell IWM, biotech, IBB, and XBI.

From a Wyckoff perspective, for short candidates, these are the ones to watch (not advice, not a recommendation).

Biotech, XBI

As stated in the prior update, XBI may have formed a triple top within and ‘up-thrust’, link here.

The obvious areas to watch for today’s session, are yesterday’s high and low.

A new high puts the up-thrust into question; new low, adds (a small) confirmation to reversal.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … The Big One?

September 10, 2025 By in $SPSIBI, Biotech, GDX, GDXJ, Gold & Silver, Gold Miners, Greg Hunter, HOOD, IBB, Karen Kingston, LABD, LABD-25-10, Nasdaq, ORCL, Positions, QQQ, S&P, S&P 500, SPBIO, Speck-Effect, SPY, The Speck, XBI 3 Comments

Next Leg Lower

Unfortunately, the (mad scientist) graphic at left, is not too far removed from what’s really going on in biotech.

While the S&P, Nasdaq Qs, Gold Miners, Semiconductors, Financials, The HOOD, ORCL, and others, continue to make all-time highs, conspicuously absent is biotech, XBI and IBB.

Now, it appears that quietly, in the background, XBI is reversing to the downside.

Biotech XBI, Daily Close

The up-thrust is there, but is a weak penetration of resistance.

Even so, on the ‘test’, volume contracted by -49.24%, when compared to volume on the upside penetration.

Until proven otherwise, this set-up appears to (currently) be the best short opportunity.

With that said, all other short positions have been closed to focus on biotech.

Leveraged inverse fund LABD is being used at this juncture: Trade LABD-25-10, with stop at the session low (not advice, not a reocmmendiaton).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279